The paper's citation list
No. | The paper's citation list |
|---|
1 | Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine 2024;133 doi:https://doi.org/10.1016/j.jnutbio.2024.109704 |
2 | From Hypothalamic Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics 2024;14 doi:https://doi.org/10.3390/metabo14080408 |
3 | Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists 2024;212 doi:https://doi.org/10.1016/j.diabres.2024.111689 |
4 | The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene–diet study from the UK Biobank 2024;119:417-424 doi:https://doi.org/10.1016/j.ajcnut.2023.11.012 |
5 | Liver stiffness as a cornerstone in heart disease risk assessment 2024;44:344-356 doi:https://doi.org/10.1111/liv.15801 |
6 | Pathophysiological hallmarks in type 2 diabetes heterogeneity (review) 2024 doi:https://doi.org/10.1007/s13340-024-00783-w |
7 | Editorial-Reflecting on three years of M&TOD-Where we are and where we are going 2024;4 doi:https://doi.org/10.20517/mtod.2024.65 |
8 | Metabolic-associated fatty liver disease is associated with colorectal adenomas in young and older Korean adults 2023;43:2548-2559 doi:https://doi.org/10.1111/liv.15738 |
9 | Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study 2023;49 doi:https://doi.org/10.1016/j.diabet.2023.101454 |
10 | Adiposity, hepatic steatosis, and metabolic health transitions in people with obesity: Influences of age and sex 2023;33:1149-1157 doi:https://doi.org/10.1016/j.numecd.2023.03.020 |
11 | Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease 2023;57:872-885 doi:https://doi.org/10.1111/apt.17362 |
12 | Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality 2023;3 doi:https://doi.org/10.20517/mtod.2022.23 |
13 | Emerging role of aging in the progression of NAFLD to HCC 2023;84 doi:https://doi.org/10.1016/j.arr.2022.101833 |
14 | Association between type 2 diabetes mellitus and prostate cancer 2023;3 doi:https://doi.org/10.20517/mtod.2023.34 |
15 | The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers 2023;16:891-911 doi:https://doi.org/10.1080/17512433.2023.2259306 |
16 | Male hypogonadism in overweight and obesity 2023;3 doi:https://doi.org/10.20517/mtod.2023.05 |
17 | Concise review: gamma-glutamyl transferase-evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk 2022;2 doi:https://doi.org/10.20517/mtod.2022.20 |
18 | Sex- and gender-differences in chronic long-term complications of type 1 and type 2 diabetes mellitus in Italy 2022;32:2297-2309 doi:https://doi.org/10.1016/j.numecd.2022.08.011 |
19 | Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction 2022;2 doi:https://doi.org/10.20517/mtod.2022.14 |
20 | Towards Multiplexed and Multimodal Biosensor Platforms in Real-Time Monitoring of Metabolic Disorders 2022;22 doi:https://doi.org/10.3390/s22145200 |
21 | Precision medicine in nonalcoholic fatty liver disease 2022;37:1175-1178 doi:https://doi.org/10.1111/jgh.15850 |
22 | Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study 2022;41:1483-1490 doi:https://doi.org/10.1016/j.clnu.2022.05.009 |
23 | SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis 2022;23:2191-2197 doi:https://doi.org/10.31557/APJCP.2022.23.7.2191 |
24 | What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD): MAFLD heterogeneity 2021;72 doi:https://doi.org/10.1016/j.ebiom.2021.103584 |
25 | Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine 2021;2:435-442 doi:https://doi.org/10.37349/emed.2021.00061 |
